BNP Paribas Financial Markets Purchases 795 Shares of XOMA Co. (NASDAQ:XOMA)

BNP Paribas Financial Markets grew its position in shares of XOMA Co. (NASDAQ:XOMA) by 95.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,632 shares of the biotechnology company’s stock after buying an additional 795 shares during the quarter. BNP Paribas Financial Markets’ holdings in XOMA were worth $43,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ellsworth Advisors LLC purchased a new position in XOMA in the third quarter worth $516,000. Bank of New York Mellon Corp increased its position in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Price Performance

XOMA stock opened at $25.11 on Friday. The business’s 50 day simple moving average is $30.01 and its 200 day simple moving average is $27.72. XOMA Co. has a 12 month low of $17.52 and a 12 month high of $35.00. The company has a market cap of $295.87 million, a price-to-earnings ratio of -7.22 and a beta of 0.88. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Buying and Selling at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $123.00 price target on shares of XOMA in a research report on Friday, December 13th.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.